WebIn November 2024, Chidamide was approved by the NMPA in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone receptor-positive, HER2-negative, recurrent or progressive locally advanced or metastatic breast cancer previously treated with endocrine therapy. WebBiocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China… Jie Xiang 分享 Didn't expect first senior-authored article came from industry.
Find Pipelines Near You - pipeline awareness
WebApr 11, 2024 · Request for a sample report to understand more about the Systemic Lupus Erythematosus pipeline development activities ... Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and ... WebJun 24, 2024 · SHENZHEN, China, June 24, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat... birthday ice cream cake pictures
Find Pipelines Near You - pipeline awareness
WebSHENZHEN, China, April 16, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique technology of Chemical Genomics Drug discovery platform, today announces that it has received... Apr 16, 2024. www.prnewswire.com. WebApr 14, 2024 · Recently Concluded Data & Programmatic Insider Summit March 22 - 25, 2024, Scottsdale Digital OOH Insider Summit February 19 - 22, 2024, La Jolla WebFeb 28, 2024 · Chipscreen NewWay will make a $5.74m (¥40m) upfront payment to Eucure Biopharma and up to $51.7m (¥360m) in potential development milestone payment. Eucure Biopharma will receive up to $28.17m (¥196m) in potential sales milestone payment and tiered royalties on net sales. birthday ice cream cupcakes